Search results

This month ANSTO is opening its doors to 11 talented young people from across Australia as the two-year Graduate Program kickstarts.

Peter Kabokov will continue work that will contribute to defence industry

The Australian Nuclear Medicine Traceability Program (ANMTP) assists practices administering nuclear medicine-based radionuclides to achieve regulatory compliance by providing measurement traceability to the Australian Standard.

Research to detect and measure air pollution, the composition the atmosphere and mixing in the atmosphere.

Measurement research undertaken to ensure safe, well-engineered nanoparticles

PhD candidate Vienna Wong is using her FutureNow Scholarship to research ultra-high temperature ceramics, which are emerging materials for extreme environments.

A groundbreaking international study has provided new insights into global fossil methane emissions, using innovative multi-isotopic atmospheric measurements.  

This week, ANSTO hosted the 10th annual Regional Advisory Safety Committee for research reactors in Asia pacific (RASCAP). This a joint IAEA-Asian Nuclear Safety Network (ANSN) supported forum to foster networking and regional cooperation, and for facilitating use of competencies in the region to cover specific safety issues in research reactors.

ANSTO is interested finding students to collaborate on Generation IV reactor systems.

Specifications, Beryllium Filter, User Manual, Instrument reference

ANSTO, Australia’s knowledge centre for nuclear science and technology, connects STEM graduates with industry to work on real-world challenges through its FutureNow Scholarships for 2022.

Technique provides insights into historic maritime artefact linked to early exploration of Australia.

ANSTO’s Innovation Precinct welcomes NSW Government’s $12.5 commitment funding.

A new radiocarbon dating facility opened at the University of New South Wales (UNSW) will complement the extensive radiocarbon facilities at ANSTO’s world-leading Centre for Accelerator Science

Scandium 47, a therapeutic radioisotope and potential theranostic, has been produced for the first time at ANSTO. Theranostics are used to both diagnose and treat disease.